Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal Cancer With Previous Standard Treatment Failure ：an Exploratory, Single-arm, Open-label, Phase II Trial

NCT05225844 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT05225844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05225844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal Cancer With Previous Standard Treatment Failure ：an Exploratory, Single-arm, Open-label, Phase II Trial
Lead sponsor
Harbin Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2019
Completion date
October 1, 2022
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal cancer, immunotherapy, targeted therapy